$4.49
Ardelyx
Performance
Dividends
-15.92%
1W
1M
YTD
1Y
3Y
22/36
Growth Score
9/36
Dividend Score
Valuation
PE Ratio
-19.93
PS Ratio
2.97
RSI
-
0
PEG Ratio
-0.06
3
PRG Ratio
0.01
PDG Ratio
0
Growth
3139%3168%011%233%
2%41%-74%114%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
96.37%
3
Gross Margin
85.08%
3
Current Ratio
4.12
Return on Assets
-13.11%
Return on Equity
-34.45%
Return on inv. Capital
-12.03%
Institutional Holder
172.266.6120184.174.339
1882233
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 333.62M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -39.14M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 283.06M
2018
2019
2020
2021
2022
2023
2024
6
Events
ARDX
Ardelyx
in 285 days
after market close
Earnings per Share is expected with - and revenue with - .
ARDX
Ardelyx
in 215 days
after market close
Earnings per Share is expected with - and revenue with - .
ARDX
Ardelyx
in 103 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
19.06.2014
MaketCap
1.07B
Country
US
CEO
Michael G. Raab
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Updated 12.07.2025